Exelixis Inc

NASDAQ:EXEL  
21.81
-0.03 (-0.14%)
Products

Exelixis Announces U.S. FDA Approval Of Cabometyx (Cabozantinib) For Patients With Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Published: 09/17/2021 20:31 GMT
Exelixis Inc (EXEL) - Exelixis Announces U.S. FDA Approval of Cabometyx® (cabozantinib) for Patients With Previously Treated Radioactive Iodine-refractory Differentiated Thyroid Cancer.
Exelixis Inc - is Prepared to Fully Support Expanded Indication Immediately.
Exelixis Inc - Application Approved Well Ahead of Prescription Drug User Fee Act Target Action Date of December 4, 2021.